by dyadic | Jun 2, 2022 | Press Releases
JUPITER, Fla., June 02, 2022 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein...
by dyadic | May 20, 2022 | Press Releases
JUPITER, Fla., May 20, 2022 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI) a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein...
by dyadic | May 12, 2022 | Press Releases
New research, license, and collaboration agreement with a Global Food Ingredients Company using Dyadic’s proprietary biotechnologiesLicense agreement with Phibro/Abic Animal Health to develop and commercialize animal vaccine(s)Advancing first-in-human clinical...
by dyadic | May 11, 2022 | Press Releases
JUPITER, Fla., May 11, 2022 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving,...
by dyadic | May 9, 2022 | Press Releases
Toxicology data published in the international peer-reviewed scientific journal “Toxicologic Pathology” demonstrates excellent safety profile and lasting immunogenic response from Dyadic’s DYAI-100, recombinant protein receptor binding domain (RBD)...
by dyadic | Apr 28, 2022 | Press Releases
JUPITER, Fla., April 28, 2022 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving,...
